Rashtriya Newsflash

DelveInsight’s “Excessive Daytime Sleepiness Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Excessive Daytime Sleepiness, historical and forecasted epidemiology as well as the Excessive Daytime Sleepiness market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Get a Free sample for the Excessive Daytime Sleepiness Market Report:

https://www.delveinsight.com/report-store/excessive-daytime-sleepiness-eds-market

Some of the key facts of the Excessive Daytime Sleepiness Market Report:

• The Excessive Daytime Sleepiness market size was valued at approximately USD 7,500 million in 2025 and is anticipated to grow at a CAGR of 3% during the forecast period from 2026 to 2036.

• XYWAV generated the highest revenue in the narcolepsy segment, reaching approximately USD 1,130 million in 2025.

• Several therapies are approved across the 7MM for the treatment of Excessive Daytime Sleepiness, including PROVIGIL/MODIODAL (modafinil), NUVIGIL (armodafinil), SUNOSI (solriamfetol), WAKIX (pitolisant), XYWAV (calcium, magnesium, potassium, and sodium oxybates), and XYREM (sodium oxybate). Generic versions of PROVIGIL/MODIODAL, NUVIGIL, and XYREM are also available in the US market.

• In February 2026, Wakix (pitolisant) is a prescription therapy indicated for narcolepsy, a chronic neurological sleep disorder characterized by excessive daytime sleepiness and, in many patients, cataplexy sudden episodes of muscle weakness often triggered by strong emotions. The U.S. Food and Drug Administration (FDA) has approved Wakix for the treatment of cataplexy in pediatric patients aged 6 years and older who have narcolepsy.

• In January 2025, Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing treatments for hypertension, chronic kidney disease (CKD), and other conditions driven by dysregulated aldosterone, has announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) Application. This approval allows the company to conduct a Phase 2 clinical trial to assess the effects of lorundrostat in treating patients with moderate-to-severe obstructive sleep apnea (OSA) and hypertension.

• The total number of diagnosed prevalent cases of Excessive Daytime Sleepiness in the 7MM was around 7,800,000 in 2025.

• The United States encompasses the highest diagnosed prevalent population of Excessive Daytime Sleepiness, around 4,200,000 in 2025.

• Among EU4 and the UK, the UK accounts for the highest number of diagnosed prevalent cases of Excessive Daytime Sleepiness, whereas Spain accounts for the least number of prevalent cases.

• As per the DelveInsight analysis, it was observed that Japan accounted for approximately 16% of the diagnosed prevalent population of Excessive Daytime Sleepiness among 7MM, in the year 2025.

• Key Excessive Daytime Sleepiness Companies: Avadel Pharmaceuticals, Axsome Therapeutics, Theranexus, Suven LifeSciences, NLS Pharma, XWPharma, Balance Therapeutics, Takeda Pharmaceuticals, Benevolent AI Bio, Avadel Pharmaceuticals, and others

• Key Excessive Daytime Sleepiness Therapies: FT218, THN102, SUVN-G3031, Quilience, XW10172, TAK-994, BEN-2001, AXS-12 (Reboxetine), Xywav (JZP-258) for EDS in IH, Wakix (Pitolisant) for EDS in OSA, and others

• The Excessive Daytime Sleepiness epidemiology based diagnosed prevalent cases analyzed that in the US, the majority of the cases of EDS are found in OSA and Bipolar disorder, followed by Parkinson’s Disease, Narcolepsy, and Idiopathic Hypersomnia

• The Excessive Daytime Sleepiness market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Excessive Daytime Sleepiness pipeline products will significantly revolutionize the Excessive Daytime Sleepiness market dynamics.

Excessive Daytime Sleepiness Overview

The condition known as excessive daytime sleepiness (EDS) is characterised by difficulty remaining awake and alert during the day’s main waking periods, with sleep happening accidentally or at inopportune times.

To Know in detail about the Excessive Daytime Sleepiness market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Excessive Daytime Sleepiness Market Forecast

Excessive Daytime Sleepiness Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Excessive Daytime Sleepiness Epidemiology Segmentation:

The Excessive Daytime Sleepiness market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness

• Total Diagnosed Prevalent Cases of Excessive Daytime Sleepiness in Different Disorders

• Total Treatable Cases of Excessive Daytime Sleepiness

Download the report to understand which factors are driving Excessive Daytime Sleepiness epidemiology trends @ Excessive Daytime Sleepiness Epidemiology Forecast

Excessive Daytime Sleepiness Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Excessive Daytime Sleepiness market or expected to get launched during the study period. The analysis covers Excessive Daytime Sleepiness market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Excessive Daytime Sleepiness Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Excessive Daytime Sleepiness Therapies and Key Companies

• Pitolisant (WAKIX/OZAWADE): Bioprojet Pharma/Harmony Biosciences

• Solriamfetol (SUNOSI): Jazz Pharmaceuticals

• FT218: Avadel Pharmaceuticals

• Xywav (calcium, magnesium, potassium, and sodium oxybates): Jazz Pharmaceuticals

• Xyrem (sodium oxybate): Jazz Pharmaceuticals/UCB Pharma Ltd

• Samelisant (SUVN-G3031): Suven Life Sciences

• AXS-12: AxsomeTherapeutics

• THN102: Theranexus

• SUVN-G3031: Suven LifeSciences

• Quilience: NLS Pharma

• XW10172: XWPharma

• TAK-994: Takeda

Discover more about therapies set to grab major Excessive Daytime Sleepiness market share @ Excessive Daytime Sleepiness Treatment Market

Excessive Daytime Sleepiness Market Drivers

• Rising Prevalence of Sleep Disorders: Increasing cases of narcolepsy, obstructive sleep apnea, insomnia, and other neurological disorders are driving demand for Excessive Daytime Sleepiness (EDS) treatments.

• Growing Awareness and Diagnosis Rates: Improved awareness regarding sleep health and advancements in diagnostic technologies are leading to earlier detection and treatment of EDS conditions.

• Advancements in Therapeutics: The introduction of novel wake-promoting agents and innovative treatment approaches is expanding therapeutic options for EDS patients.

• Increasing Healthcare Expenditure: Rising investments in sleep medicine, neurological care, and healthcare infrastructure are supporting market growth.

Excessive Daytime Sleepiness Market Barriers

• High Treatment Costs: Premium pricing of branded therapies and long-term treatment expenses may limit patient accessibility in certain regions.

• Availability of Generic Alternatives: The presence of generic versions of key EDS therapies creates pricing pressure for branded products.

• Underdiagnosis of Sleep Disorders: Many EDS cases remain undiagnosed or misdiagnosed due to limited awareness and lack of specialized sleep centers.

• Side Effects and Safety Concerns: Some wake-promoting drugs may be associated with cardiovascular, psychiatric, or dependency-related side effects, affecting patient adherence.

• Stringent Regulatory Requirements: Complex clinical trial and approval processes for central nervous system (CNS) therapies can delay product launches.

Scope of the Excessive Daytime Sleepiness Market Report

• Study Period: 2022–2036

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Excessive Daytime Sleepiness Companies: Avadel Pharmaceuticals, Axsome Therapeutics, Theranexus, Suven LifeSciences, NLS Pharma, XWPharma, Balance Therapeutics, Takeda Pharmaceuticals, Benevolent AI Bio, Avadel Pharmaceuticals, and others

• Key Excessive Daytime Sleepiness Therapies: FT218, THN102, SUVN-G3031, Quilience, XW10172, TAK-994, BEN-2001, AXS-12 (Reboxetine), Xywav (JZP-258) for EDS in IH, Wakix (Pitolisant) for EDS in OSA, and others

• Excessive Daytime Sleepiness Therapeutic Assessment: Excessive Daytime Sleepiness current marketed and Excessive Daytime Sleepiness emerging therapies

• Excessive Daytime Sleepiness Market Dynamics: Excessive Daytime Sleepiness market drivers and Excessive Daytime Sleepiness market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Excessive Daytime Sleepiness Unmet Needs, KOL’s views, Analyst’s views, Excessive Daytime Sleepiness Market Access and Reimbursement

To know more about Excessive Daytime Sleepiness companies working in the treatment market, visit @ Excessive Daytime Sleepiness Clinical Trials and Therapeutic Assessment

Table of Contents

1. Excessive Daytime Sleepiness Market Report Introduction

2. Executive Summary for Excessive Daytime Sleepiness

3. SWOT analysis of Excessive Daytime Sleepiness

4. Excessive Daytime Sleepiness Patient Share (%) Overview at a Glance

5. Excessive Daytime Sleepiness Market Overview at a Glance

6. Excessive Daytime Sleepiness Disease Background and Overview

7. Excessive Daytime Sleepiness Epidemiology and Patient Population

8. Country-Specific Patient Population of Excessive Daytime Sleepiness

9. Excessive Daytime Sleepiness Current Treatment and Medical Practices

10. Excessive Daytime Sleepiness Unmet Needs

11. Excessive Daytime Sleepiness Emerging Therapies

12. Excessive Daytime Sleepiness Market Outlook

13. Country-Wise Excessive Daytime Sleepiness Market Analysis (2022–2036)

14. Excessive Daytime Sleepiness Market Access and Reimbursement of Therapies

15. Excessive Daytime Sleepiness Market Drivers

16. Excessive Daytime Sleepiness Market Barriers

17. Excessive Daytime Sleepiness Appendix

18. Excessive Daytime Sleepiness Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/
Country: United States
Website: https://www.delveinsight.com/